Structural characterization of phosphoethanolamine-modified lipid A from probiotic Escherichia coli strain Nissle 1917
Open Access
- 25 June 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 9 (34) , 19762-19771
Abstract
Gut microbiota, a complex microbial community inhabiting human or animal intestines recently regarded as an endocrine organ, has a significant impact on human health. Probiotics can modulate gut microbiota and the gut environment by releasing a range of bioactive compounds. Escherichia coli (E. coli) strain Nissle 1917 (EcN), a Gram-negative bacterial strain, has been used to treat gastrointestinal (GI) disorders (i.e., inflammatory bowel disease, diarrhea, ulcerative colitis, and so on). However, endotoxicity of lipopolysaccharide (LPS), a major component of the cell wall of Gram-negative bacteria in the gut, is known to have a strong influence on gut inflammation and maintenance of gut homeostasis. Therefore, characterizing the chemical structure of lipid A which determines the toxicity of LPS is needed to understand nonpathogenic colonization and commensalism properties of EcN in the gut more precisely. In the present study, MALDI multiple-stage mass spectrometry analysis of lipid A extracted from EcN demonstrates that hexaacylated lipid A (m/z 1919.19) contains a glucosamine disaccharide backbone, a myristate, a laurate, four 3-hydroxylmyristates, two phosphates, and phosphoethanolamine (PEA). PEA modification of lipid A is known to contribute to cationic antimicrobial peptide (CAMP) resistance of Gram-negative bacteria. To confirm the role of PEA in CAMP resistance of EcN, minimum inhibitory concentrations (MICs) of polymyxin B and colistin were determined using a wild-type strain and a mutant strain with deletion of eptA gene encoding PEA transferase. Our results confirmed that MICs of polymyxin B and colistin for the wild-type were twice as high as those for the mutant. These results indicate that EcN can more efficiently colonize the intestine through PEA-mediated tolerance despite the presence of CAMPs in human gut such as human defensins. Thus, EcN can be used to help treat and prevent many GI disorders.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2015M1A5A1037196, NRF-2017M3A9B6062989, NRF-2017M3A9E4077234, NRF-2018R1D1A1B07048185)
This publication has 49 references indexed in Scilit:
- The gut microbiome: the role of a virtual organ in the endocrinology of the hostJournal of Endocrinology, 2013
- From agonist to antagonist: Structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxinsMolecular Immunology, 2011
- A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer MembraneAntimicrobial Agents and Chemotherapy, 2010
- Probiotics promote gut health through stimulation of epithelial innate immunityProceedings of the National Academy of Sciences, 2009
- A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti‐inflammatory effects in lipopolysaccharide‐induced sepsis in miceBritish Journal of Pharmacology, 2009
- Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolitesProceedings of the National Academy of Sciences of the United States of America, 2009
- The non-pathogenicEscherichia colistrain Nissle 1917 – features of a versatile probioticMicrobial Ecology in Health and Disease, 2009
- Lipid A Modification Systems in Gram-Negative BacteriaAnnual Review of Biochemistry, 2007
- The co-evolution of host cationic antimicrobial peptides and microbial resistanceNature Reviews Microbiology, 2006
- Ion formation in MALDI mass spectrometryMass Spectrometry Reviews, 1998